Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622331 | 0.96 | HRH3 (0.75) | HRH3DRD2ALDH1A1HPGDMAOB | |
| Oxalic Acid SCHEMBL4498003 | 0.92 | HRH3 (0.66) | HRH3KDM4EDRD2ALDH1A1HPGD | |
| Oxalic Acid SCHEMBL4508710 | 0.92 | HRH3 (0.66) | HRH3KDM4EDRD2ALDH1A1HPGD | |
| Oxalic Acid SCHEMBL4507574 | 0.89 | HRH3 (0.62) | HRH3KDM4EDRD2ALDH1A1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL4483634 | 0.89 | HRH3 (0.62) | HRH3KDM4EDRD2ALDH1A1SMN1; SMN2 | |
| Oxalic Acid SCHEMBL4486834 | 0.89 | HRH3 (0.66) | HRH3DRD2 | |
| Oxalic Acid SCHEMBL4488730 | 0.89 | HRH3 (0.62) | HRH3KDM4EDRD2ALDH1A1 | |
| SCHEMBL4621668 | 0.88 | HRH3 (0.70) | HRH3DRD2ALDH1A1HPGDMAOB | |
| SCHEMBL4619979 | 0.88 | HRH3 (0.70) | HRH3DRD2ALDH1A1HPGDMAOB | |
| Oxalic Acid SCHEMBL4494998 | 0.87 | HRH3 (0.93) | HRH3KDM4EALDH1A1MAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576120-B2 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-08-18 | — | — | US | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | HRH3 9/4885KDM4E 461/4885DRD2 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.